Skip to main content

Advertisement

Table 3 Total adverse events

From: Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial

  No of patients (%) / No of events
  (N=17) / (N=36)
Gastrointestinal  
 Oral mucositis 5 (29.4%) / 7
 Diarrhoea 3 (17.6%) / 5
Skin-related  
 Acneiform rash 2 (11.8%) / 2
 Exacerbation of erythema nodosum 1 ( 5.9%) / 2
nodosum
Metabolic or laboratory  
 Hypertriglyceridemia 5 (29.4%) / 5
 Microcytosis and hypochromia 3 (17.6%) / 3
Gynaecological  
 Menstruation disturbances 3 (17.6%) / 3
Renal  
 Nephrotic range proteinuria 1 ( 5.9%) / 1
 MAU <2 x ULN 3 (17.6%) / 3
 MAU 2–3 x ULN 2 (11.8%) / 2
 MAU 3 x ULN 2 (11.8%) / 2
 Acute pyelonephritis 1 ( 5.9%) / 1
  1. MAU: microalbuminuria.
  2. ULN: upper limit of normality.